Skip to content
← Full study record

NCT00092521 · MORE INFO

Limitations, agreements, and source contact

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) · Source last updated 2015-09-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialsDisclosure@merck.com
organization
Merck Sharp & Dohme Corp.
phone
1-800-672-6372
title
Executive Vice President, Clinical and Quantitative Sciences
Complete source fields
certain Agreement
other Details
Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialsDisclosure@merck.com
organization
Merck Sharp & Dohme Corp.
phone
1-800-672-6372
title
Executive Vice President, Clinical and Quantitative Sciences

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice